TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating restated by equities research analysts at Raymond James in a research report issued to clients and investors on Thursday.
The analysts wrote, “We are reiterating our Strong Buy rating on TG Therapeutics. At the 2018 American Association of Cancer Research (AACR) annual meeting, the company presented a poster featuring preclinical data of a BET inhibitor (TG-1601), which, based on our analysis of the data, supports clinical evaluation of this compound in combination with the company’s other pipeline products. Separately, in the PI3K delta world, Incyte presented clinical data of its PI3K delta inhibitor (INCB050465) in combination with pembrolizumab (Pembro) in solid tumors, demonstrating that PI3K delta inhibition appeared to synergize with PD-1 blockade. We view the totality of the clinical findings as great news for TG Therapeutics given that the company may have a best-in-class PI3K delta inhibitor, which could also demonstrate synergistic clinical effects when combined with a PD-1/PD-L1 inhibitor.””
A number of other equities research analysts also recently commented on TGTX. HC Wainwright reiterated a “buy” rating and set a $33.00 price objective on shares of TG Therapeutics in a research report on Monday, January 8th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. Zacks Investment Research downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. B. Riley reiterated a “buy” rating and set a $21.50 price objective on shares of TG Therapeutics in a research report on Wednesday, January 17th. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $24.60.
Shares of NASDAQ:TGTX opened at $14.40 on Thursday. TG Therapeutics has a one year low of $7.25 and a one year high of $17.35. The firm has a market cap of $1,073.23, a PE ratio of -7.54 and a beta of 1.20.
TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, meeting analysts’ consensus estimates of ($0.46). TG Therapeutics had a negative return on equity of 145.58% and a negative net margin of 77,945.40%. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. sell-side analysts forecast that TG Therapeutics will post -1.68 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC lifted its holdings in shares of TG Therapeutics by 14.0% in the fourth quarter. Segall Bryant & Hamill LLC now owns 61,092 shares of the biopharmaceutical company’s stock valued at $501,000 after purchasing an additional 7,500 shares in the last quarter. MetLife Investment Advisors LLC purchased a new stake in shares of TG Therapeutics during the fourth quarter worth $172,000. BB&T Securities LLC raised its holdings in shares of TG Therapeutics by 153.4% during the fourth quarter. BB&T Securities LLC now owns 33,700 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 20,400 shares in the last quarter. Nexthera Capital LP purchased a new stake in shares of TG Therapeutics during the fourth quarter worth $246,000. Finally, Raymond James & Associates raised its holdings in shares of TG Therapeutics by 137.2% during the fourth quarter. Raymond James & Associates now owns 211,595 shares of the biopharmaceutical company’s stock worth $1,735,000 after acquiring an additional 122,400 shares in the last quarter. Institutional investors own 47.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/21/tg-therapeutics-tgtx-rating-reiterated-by-raymond-james.html.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.